External, non-payer generated data can inform formulary decision-making—if payers know their strengths and weaknesses.
The specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.
Value-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.
Recent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.
Biosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.
Oncology is a complex and rapidly-evolving management challenge for payers.
Just last year, the FDA approved Exondys 51 (eteplirsen) for DMD, over the recommendations of FDA scientists and an external scientific advisory committee. Read more.
Weighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.
Patient risk can improve value-based cancer care. Find out how.
How managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting.